Long-term outcome of bosentan treatment in idiopathic pulmonary arterial hypertension and pulmonary arterial hypertension associated with the scleroderma spectrum of diseases

Journal of Heart and Lung Transplantation

Volumn 24, Issue 10, 2005, Pages 1626-1631

  Girgis, Reda E ^a   Mathai, Stephen C ^a   Krishnan, Jerry A ^a   Wigley, Fredrick M ^a   Hassoun, Paul M ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOSENTAN;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADULT; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DEATH; DISEASE ASSOCIATION; DRUG EFFECT; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEALTH CENTER; HUMAN; IDIOPATHIC DISEASE; IDIOPATHIC PULMONARY ARTERIAL HYPERTENSION; LIVER TOXICITY; LONG TERM CARE; MALE; MONOTHERAPY; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SCLERODERMA; SIDE EFFECT; SURVIVAL RATE; TIME; TREATMENT OUTCOME; WORLD HEALTH ORGANIZATION;

ADULT; AGED; ANTIHYPERTENSIVE AGENTS; EXERCISE TOLERANCE; FEMALE; FOLLOW-UP STUDIES; HEMODYNAMIC PROCESSES; HEPATITIS, TOXIC; HUMANS; HYPERTENSION, PULMONARY; MALE; MIDDLE AGED; RECOVERY OF FUNCTION; SCLERODERMA, SYSTEMIC; SULFONAMIDES; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 25844531004     PISSN: 10532498     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.healun.2004.12.113     Document Type: Article

References (30)

1. R.N. Channick, G. Simonneau, O. Sitbon Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension a randomised placebo-controlled study Lancet 358 2001 1119 1123
2. L.J. Rubin, D.B. Badesch, R.J. Barst Bosentan therapy for pulmonary arterial hypertension N Engl J Med 346 2002 896 903
3. O. Sitbon, D.B. Badesch, R.N. Channick Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary arterial hypertension a 1-year follow-up study Chest 124 2003 247 254
4. S.M. Kawut, D.B. Taichman, C.L. Archer-Chicko, H.I. Palevsky, S.E. Kimmel Hemodynamics and survival in patients with pulmonary arterial hypertension related to systemic sclerosis Chest 123 2003 344 350
5. K.P. Kuhn, D.W. Byrne, P.G. Arbogast, T.P. Doyle, J.E. Loyd, I.M. Robbins Outcome in 91 consecutive patients with pulmonary arterial hypertension receiving epoprostenol Am J Respir Crit Care Med 167 2003 580 586
6. S. Rich, D.R. Dantzker, S.M. Ayres Primary pulmonary hypertension. A national prospective study Ann Intern Med 107 1987 216 223
7. D.B. Badesch, V.F. Tapson, M.D. McGoon Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial Ann Intern Med 132 2000 425 434
8. E.C. LeRoy, T.A. Medsger Jr Criteria for the classification of early systemic sclerosis J Rheumatol 28 2001 1573 1576
9. G. Simonneau, N. Galie, L.J. Rubin Clinical classification of pulmonary hypertension J Am Coll Cardiol 43 12 Suppl S 2004 5S 12S
10. G. Simonneau, M. Fartoukh, O. Sitbon, M. Humbert, J.L. Jagot, P. Herve Primary pulmonary hypertension associated with the use of fenfluramine derivatives Chest 114 3 Suppl 1998 195S 199S
11. M. McGoon, D. Gutterman, V. Steen Screening, early detection, and diagnosis of pulmonary arterial hypertension ACCP evidence-based clinical practice guidelines Chest 126 1 Suppl 2004 14S 34S
12. E.T. Koh, P. Lee, D.D. Gladman, M. Abu-Shakra Pulmonary hypertension in systemic sclerosis an analysis of 17 patients Br J Rheumatol 35 1996 989 993
13. D.G. Sacks, Y. Okano, V.D. Steen, E. Curtiss, L.S. Shapiro, T.A. Medsger Jr Isolated pulmonary hypertension in systemic sclerosis with diffuse cutaneous involvement association with serum anti-U3RNP antibody J Rheumatol 23 1996 639 642
14. A.M. Stupi, V.D. Steen, G.R. Owens, E.L. Barnes, G.P. Rodnan, T.A. Medsger Jr Pulmonary hypertension in the CREST syndrome variant of systemic sclerosis Arthritis Rheum 29 1986 515 524
15. G.E. D'Alonzo, R.J. Barst, S.M. Ayres Survival in patients with primary pulmonary hypertension. Results from a national prospective registry Ann Intern Med 115 1991 343 349
16. R.J. Barst, L.J. Rubin, W.A. Long A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group N Engl J Med 334 1996 296 302
17. V.V. McLaughlin, A. Shillington, S. Rich Survival in primary pulmonary hypertension the impact of epoprostenol therapy Circulation 106 2002 1477 1482
18. K.A. Fagan, D.B. Badesch Pulmonary hypertension associated with connective tissue disease Prog Cardiovasc Dis 45 2002 225 234
19. D. Mukerjee, D. St George, B. Coleiro Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension application of a registry approach Ann Rheum Dis 62 2003 1088 1093
20. V. McLaughlin, O. Sitbon, L.J. Rubin The effect of first-line bosentan on survival of patients with primary pulmonary hypertension [abstract] Am J Respir Crit Care Med 167 2003 A442
21. O. Sitbon, V. McLaughlin, D.B. Badesch Comparison of two treatment strategies, first-line bosentan or epoprostenol, on survival in class III idiopathic pulmonary arterial hypertension [abstract] Am J Respir Crit Care Med 169 2004 A210
22. N. Galie, W. Seeger, R. Naeije, G. Simonneau, L.J. Rubin Comparative analysis of clinical trials and evidence-based treatment algorithm in pulmonary arterial hypertension J Am Coll Cardiol 43 12 Suppl S 2004 81S 88S
23. C.D. Cool, D. Kennedy, N.F. Voelkel, R.M. Tuder Pathogenesis and evolution of plexiform lesions in pulmonary hypertension associated with scleroderma and human immunodeficiency virus infection Hum Pathol 28 1997 434 442
24. R.H. Young, G.J. Mark Pulmonary vascular changes in scleroderma Am J Med 64 1978 998 1004
25. S.A. Yousem The pulmonary pathologic manifestations of the CREST syndrome Hum Pathol 21 1990 467 474
26. O. Sitbon, M. Humbert, X. Jais Acute vasodilator responsiveness and long-term response to calcium-channel blockers in different forms of pulmonary arterial hypertension Am J Respir Crit Care Med 169 2004 A210
27. C. Strange, M. Bolster, J. Mazur, M. Taylor, J.R. Gossage, R. Silver Hemodynamic effects of epoprostenol in patients with systemic sclerosis and pulmonary hypertension Chest 118 2000 1077 1082
28. I.R. Preston, J.R. Klinger, J. Houtchens, D. Nelson, S. Mehta, N.S. Hill Pulmonary edema caused by inhaled nitric oxide therapy in two patients with pulmonary hypertension associated with the CREST syndrome Chest 121 2002 656 659
29. H.W. Farber, K.K. Graven, G. Kokolski, J.H. Korn Pulmonary edema during acute infusion of epoprostenol in a patient with pulmonary hypertension and limited scleroderma J Rheumatol 26 1999 1195 1196
30. M.R. Fisher, S.C. Mathai, J. Krishnan Hemodynamic and echocardiographic differences between idiopathic pulmonary arterial hypertension and pulmonary arterial hypertension related to scleroderma [abstract] Am J Respir Crit Care Med 169 2004 A173